Navigation Links
Study Finds Treatment with Metreleptin Improved Diabetes and Lipid Control in Patients with Partial Lipodystrophy
Date:6/4/2011

(pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

This press release contains forward-looking statements about Amylin which involve risks and uncertainties. The actual results for Amylin could differ materially from those discussed due to a number of risks and uncertainties, including that the CMC section of the metreleptin BLA mentioned in this press release may not be submitted in a timely fashion, the estimate of the number of lipodystrophy patients mentioned in this press release may not be accurate, clinical trials or studies may not start when planned, confirm previous results, be predictive of real world use or achieve intended clinical endpoints; preclinical studies may not be predictive; our product candidates, including the product candidate mentioned in this press release, may not receive regulatory approval; and inherent scientific, regulatory and other risks in the drug development and commercialization process. These and additional risks and uncertainties are described more fully in Amylin's most recently filed SEC documents, including its Annual Report on Form 10-K. Amylin undertakes no duty to update these forward-looking statements.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Questions Ability of Radiology Benefit Managers to Lower Costs
2. A Recent Study by ITGs Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
3. Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization
4. Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
5. Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment
6. All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated
7. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
8. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
9. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
10. U-M Study: Children Dependent on Long-Term Mechanical Ventilation Require Longer, More Expensive Hospital Care
11. Use of TIGR® Matrix Surgical Mesh in Multi-Center Randomized Controlled TRAM Flap Study Passes 20 Patient Mark and Wins Praise from Participating Surgeons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... -- Cardica, Inc. (Nasdaq: CRDC ) today announced that on ... company,s vice president of operations, was granted an option to ... per share exercise price of $0.43, the closing trading price ... to Cardica, Inc.,s Inducement Plan, which was approved by the ... of the Nasdaq Global Market for equity grants to induce ...
(Date:5/21/2015)... -- The Pharmaceutical Care Management Association (PCMA) issued ... offsets included in the Energy & Commerce Committee,s ... 21st Century Cures initiative can only be advanced by ... Medicare – then its costs outweigh any potential ... "Leveraging payments to Part D plans to ...
(Date:5/21/2015)... May 21, 2015 ... - Zwecks Leistungsvergleich zur Expertise und ... EG-Mitgliedstaaten verwiesen, in denen uneingeschränkt betriebsfähige ... Sie ein Aegate-Land: beispielsweise BELGIEN   ... Bekämpfung von Arzneimittelfälschungen (FMD) handelt es ...
Breaking Medicine Technology:Cardica Announces New Employment Inducement Grant 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 3
... Corp. has signed a consent decree agreeing to correct manufacturing quality violations at its ... $175 million in unlawful profits from the sale of products that were ... , , ... , , ...
... ExpertRECALL, the leader in the field of recall logistics and ... recall logistics management in the food, drug and consumer products industries to ... with Michaels Stores, Inc. , ... Upon completion of their studies at Saint Louis University ,s ...
Cached Medicine Technology:Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 2Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 3ExpertRECALL Awards First Scholarships for Product-Safety Education 2
(Date:5/24/2015)... 2015 EnviroLeather™ by LDI, a ... – a classic, rugged leather grain with enhanced ... stains, including ink, to be easily removed. The ... for corporate, healthcare, hospitality and education environments. , ... goal of developing products that are more sustainable, ...
(Date:5/24/2015)... Indiana Fiber Network, LLC (IFN), the leading ... America, Inc. (MTA) has selected IFN as a fiber ... Enterprise Sales Manager, fiber route diversity and network redundancy ... provides MTA with the diverse fiber transport from their ... and voice carriers located at Henry Street in Indianapolis, ...
(Date:5/24/2015)... A report out just last ... best option for avoiding cardiovascular disease is exercise and ... the single most powerful predictor of death and survival, ... and family history of premature death -- a finding ... lung fitness. , The Importance of Cardiovascular Screening , ...
(Date:5/23/2015)... 23, 2015 Dr. David Benvenuti, an experienced ... posted a new article to his website that ... Dr Benvenuti explained in the fascinating blog, he has ... their earlobes. , Known as “gauging,” the technique involves placing ... Dr. Benvenuti said will eventually stretch the holes out to ...
(Date:5/23/2015)... On May 16, the team at Farrell’s eXtreme ... mud obstacle run that raised funds for multiple sclerosis. ... the reason we participated was to support people living with ... eXtreme Bodyshaping. “One-hundred percent of the funds raised go to ... not only attended by eXtreme Bodyshaping staff, but members of ...
Breaking Medicine News(10 mins):Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2
... , , BATESVILLE, ... and Radianse today announced a strategic partnership agreement to integrate ... Nurse Call system. With this move, Hill-Rom intends to ... to remove financial and technical obstacles for health care customers ...
... , VIENNA, Va., Sept. 2 ... ), a developer of vaccines for the prevention and treatment of ... of Series K convertible notes (the "Notes"). The Notes, which ... August 2006, and were convertible into common stock. , , ...
... ... (SIAC) will host Measuring Study Endpoints in Multinational Clinical Trials: Outcomes Reported from the ... LA. , ... Horsham, PA (Vocus) September 2, 2009 --The Drug Information Association (DIA) Study ...
... , SOMERSET, N.J., Sept. 2 ... and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal ... and perennial allergic rhinitis (SAR and PAR). New ASTEPRO ... convenient once-daily dosing for patients who suffer from seasonal allergies. ...
... , PARSIPPANY, N.J., Sept. 2 The following is ... Communication about the safety review of orlistat: , , ... safety review of orlistat and liver-related serious adverse events. , , ... http://www.prnewswire.com/mnr/alli/39949/ , , It,s important consumers know ...
... , , TUCSON, Ariz., Sept. 2 ... Fletcher McCusker, Chairman and Chief Executive Officer, is scheduled to present an ... Conference on Wednesday, September 9, 2009 at The Four Seasons Hotel in ... is scheduled for 9:30 a.m. ET. The presentation will be broadcast ...
Cached Medicine News:Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 2Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 3Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 4Health News:CEL-SCI Corporation Announces Elimination of $8.3 Million Convertible Notes 2Health News:Key Stakeholders to Discuss Regulatory Issues Related to the Use of Study Endpoints in Multinational Clinical Trials 2Health News:Key Stakeholders to Discuss Regulatory Issues Related to the Use of Study Endpoints in Multinational Clinical Trials 3Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 2Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 3Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 4Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 5Health News:Video: FDA States Consumers Should Continue to Use alli 2Health News:Providence Service Corporation to Present at the Baird 2009 Healthcare Conference on September 9 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: